Dr. Andrew Sharabi, MD, PhD

Dr. Sharabi practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Sharabi's NPI, 1043531213, was assigned on June 22, 2010. Dr. Sharabi graduated from Baylor College Of Medicine in 2010. Dr. Sharabi holds California license A136977.

Dr. Sharabi's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Sharabi's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Sharabi is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Sharabi to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sharabi practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Sharabi's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Sharabi is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Sharabi's licenses on file in 2 states: California and Maryland.

Dmand AI lists bone cancer radiation, head & neck cancer radiation and prostate cancer radiation among the conditions Dr. Sharabi treats.

CMS data shows 246 Medicare services from Dr. Sharabi across 7 procedure codes in 2024, for 116 Medicare patients. Medicare paid $15,838 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 116 Medicare patients who saw Dr. Sharabi in 2024. The largest group is 65 to 74, with 66 patients. 72% of them have high blood pressure, and 67% have high cholesterol. 23% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sharabi's median patient age at 66, with 47% women.

In 2023, Dr. Sharabi wrote 12 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $290 in total drug cost. In 2020, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Sharabi for performance year 2024, reported as part of a group. Dr. Sharabi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sharabi as offering telehealth.

Dmand AI links 48 papers to Dr. Sharabi, published from 2014 to 2025. 2021 was the busiest year, with 10. The most frequent topics are Immunotherapy, Head and Neck Neoplasms and Squamous Cell Carcinoma of Head and Neck. Dr. Sharabi has published most often in Clin Cancer Res. Dr. Sharabi's most frequent co-authors are Loren K. Mell, MD, Joseph A. Califano, MD and Sangwoo Shawn Kim, MD.

Dmand AI links Dr. Sharabi to 3 clinical trials. Conditions studied include Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis and Papillomavirus Infections.

CMS Open Payments shows 78 general payments to Dr. Sharabi from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. AstraZeneca Pharmaceuticals LP paid the most, $29,154.

Dr. Sharabi graduated from Baylor College Of Medicine in 2010.

Dr. Sharabi is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.